Evaxion plans to file 2025 annual report later today

Core Viewpoint - Evaxion A/S is experiencing a slight delay in the filing and publication of its 2025 annual report due to unforeseen technical issues with external vendors, unrelated to the report's content [1][2]. Company Overview - Evaxion A/S is a clinical-stage TechBio company that utilizes its proprietary AI-Immunology™ platform to develop novel vaccines targeting cancer and infectious diseases [4][5]. - The company has a team of over 40 experts involved in the entire value chain from target discovery to clinical development [5]. Technical Issues - The technical issues causing the delay are related to regulatory filing demands and do not affect the report itself [2]. - The conference call and webcast originally scheduled for the day of the report's release have been rescheduled to the following day, March 6, at 8:30 ET / 14:30 CET [2]. Pipeline and Development - Evaxion has developed a clinical pipeline that includes both personalized and off-the-shelf cancer vaccine candidates, as well as prophylactic vaccine candidates for infectious diseases [5]. - The company's vaccine candidates aim to address high unmet medical needs, reflecting its commitment to innovative and targeted treatment options [5].